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Germline mutations in the fumarate hydratase gene at 1q43 predispose to dominantly inherited skin and uterine leiomyomata
and leiomyosarcomas. The enzyme, which is a component of the tricarboxylic acid cycle, acts as a tumour suppressor. To
evaluate fumarate hydratase in respective sporadic tumours, we analysed a series of 26 leiomyosarcomas and 129 uterine
leiomyomas (from 21 patients) for somatic mutations in fumarate hydratase and allelic imbalance around 1q43. None of the
26 leiomyosarcomas harboured somatic mutations in fumarate hydratase. Fifty per cent of leiomysarcomas tested showed
evidence of allelic imbalance at 1q, but this was not conﬁned to the vicinity of fumarate hydratase. Only 5% (seven out of
129) of the leiomyomas showed allele imbalance at 1q42-q43 and no somatic mutations in fumarate hydratase were
observed. Our ﬁndings indicate that mutations in fumarate hydratase do not play a major role in the development of sporadic
leiomyosarcomas or uterine leiomyomas.
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Leiomyosarcomas of soft tissues are rare malignant tumours that
have the phenotypic features of smooth muscle differentiation.
They develop principally in adults and in a range of body sites,
particularly the retroperitoneum, superﬁcial soft tissues, and deep
compartments of the extremities (Enzinger and Weiss, 1995; Ship-
ley, 2002). Karyotypically leiomyosarcomas are characterised by a
high-degree of chromosome instability and a wide range of anoma-
lies (Packenham et al, 1997; Wang et al, 2001; Shipley, 2002). In
contrast their benign counterpart – leiomyomas – are common,
especially uterine ﬁbroids which are the most common tumours
in women during their reproductive years (Stewart, 2001). Further-
more, leiomyomas have been reported to carry few genetic changes
(Packenham et al, 1997; Mao et al, 1999).
Little is known about the molecular basis of sporadic leiomyo-
sarcomas or leiomyomas. We have, however, recently shown that
germline mutations in the fumarate hydratase (FH) gene at chro-
mosome 1q43 cause dominantly inherited skin and uterine
leiomyomata and leiomyosarcomas (MIM: 150800; Tomlinson et
al, 2002). Fumarate hydratase which is a component of the tricar-
boxylic acid cycle, acts as a tumour suppressor, its activity being
very low or absent in tumours from individuals with leiomyoma-
tosis (Tomlinson et al, 2002).
To evaluate the role of FH in sporadic leiomyomas and leiomyo-
sarcomas, we analysed 129 uterine leiomyomas and 26
leiomyosarcomas for somatic mutations and allelic imbalance at
1q42.3-q43.
MATERIALS AND METHODS
Tumour samples
A series of 129 uterine leiomyomas (89 fresh and 40 parafﬁn
embedded samples) from 21 unselected patients (aged 37 to 50
years) were studied. Number of tumours per patient ranged from
one to 14 (average number six). Twenty-six fresh frozen leiomyo-
sarcomas were studied. All were extra-uterine tumours.
Histopathology of all tumours was re-examined, and conﬁrmed
as soft tissue leiomyosarcomas.
DNA extraction
Tissues were micro-dissected and digested with 10 mM Tris-HCl
(pH 7.5), 1 mM EDTA, 15% (w v
71) SDS, and 500 mgm l
71
proteinase K, for 16 h at 568C. DNA was precipitated with sodium
acetate and ethanol following phenol chloroform extraction.
Allele imbalance
The microsatellite markers D1S3462, D1S235, D1S2850, D1S2785,
D1S304, D1S180, D1S204, D1S547, D1S1634, D1S1609 were used to
evaluate allelic imbalance within the 13.2 Mb region between 1q42.2
and 1q44 (http://genome.ucsc.edu/goldenpath/aug2001Tracks.html).
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www.bjcancer.comD1S204 and D1S547 ﬂank FH. Forward primers were ﬂuorescently-
labelled and PCR-ampliﬁed products electrophoresed through 6%
denaturing polyacrylamide gels and products detected using ABI 377
DNAsequencers.ResultswereanalysedusingGenescanandGenotyper
software. Analyses suggestive of LOH were repeated at least once to
conﬁrm the results. Allele loss was scored if the area under an allelic
peak was reduced to 540% of its original value (compared with the
other allele).
Detection of FH mutations
PCRampliﬁcationofthe10exonsandintron–exonjunctions,including
splicesitesofFH,wascarriedoutusingtheprimerpairsdetailedinTable
1. Radio-labelled PCR products were analysed for mutations by con-
formationalsensitivegelelectrophoresis(CSGE)asdescribedpreviously
(Gangulyetal,1993).Toallowforthedetectionofsequencevariantsthat
may be rendered homozygous in tumours as a result of LOH, hetero-
duplex formation was carried out after addition of unlabelled PCR
product of the identical region from a normal control DNA. Any frag-
ments showing migration shifts were sequenced directly from the PCR
products using the ABI Ready Reaction Dye Terminator Cycle Sequen-
cing Kit and an ABI3100 Prism sequencer and analysed using the
SequenceNavigatorsoftware.Nucleotidechangesidentiﬁed werecoded
according to the genomic nucleotide sequence at Genbank (http://
www.ncbi.nlm.nih.gov/Genbank/) accession number NT_004771.
RESULTS
The FH gene is composed of 10 exons. The ﬁrst exon encodes a signal
peptide facilitating mitochondrial import of the expressed protein. We
screened the full coding sequence and splice junctions of FH in all of
the leiomyomas and leiomyosarcomas. Three nucleotide sequence
changes were identiﬁed. The ﬁrst was IVS3-22A4T, identiﬁed in
one leiomyosarcoma. The second was a synonymous substitution –
309C4T encoding alanine identiﬁed in one leiomyoma, which was
also detected in the germline. The third change was a synonymous
substitution – 927G4A encoding proline, identiﬁed in two leiomyo-
sarcomas. No missense changes or pathogenic mutations – truncating
or splice site – were detected in any of the tumours.
Thirteen of the leiomyosarcomas were assessed for allele imbal-
ance, seven showed LOH (54%). In all the cases allele imbalance
was not conﬁned to the vicinity of FH but involved the whole
region analysed. There was no evidence from the LOH data for
the existence of small-scale deletions in the eight other cases. Chro-
mosome 1q42-q43 imbalance was rare in uterine leiomyomas, only
seven of the 129 (5%) tumours displayed LOH.
DISCUSSION
Prompted by the predisposition to leiomyomata and leiomyosarco-
ma seen in carriers of germline mutations in FH we have screened
the full coding sequence and splice junctions of FH for somatic
mutation in a series of sporadic leiomyomas and leiomyosarcomas.
Although we cannot exclude the possibility that some mutations
may have been missed or cannot be detected by a PCR-based
approach, the results suggest that mutations in this gene do not
play a major role in the genesis of sporadic forms of these smooth
muscle tumours. Although in the leiomyosarcomas LOH was
common, this reﬂected extensive loss of chromosome 1q rather
than being limited to the vicinity of FH.
The tumour suppressor gene/recessive oncogene hypothesis
articulated by Knudson (1993) predicts that genes that confer an
increased risk of neoplasms as a result of germline mutations are
likely to be somatically mutated in sporadic cancers of the same type.
This has proved to be the paradigm of the RB1 gene and for several
other genes, such as APC, NF2 and TP53. FH does not appear to
conform to this model and is similar to a number of other cancer
susceptibility genes in this respect. For example, truncating muta-
tions in BRCA1 and BRCA2 confer a high risk of breast cancer, but
rarely have somatic mutations in sporadic tumours been reported
in either gene (Futreal et al, 1994; Lancaster et al, 1996; Teng et al,
1996). Similarly germline mutations in PTEN confer an elevated risk
of breast cancer in individuals with Cowden’s disease, but somatic
mutations in PTEN are rarely observed in breast cancers outside this
context (Rhei et al, 1997; Sakurada et al, 1997).
There are several possible reasons for the low frequency of FH
mutations in sporadic leiomyomas and leiomyosarcomas detected
in our study. It may be that sporadic lesions develop through a
route distinct from familial tumours. Alternatively, FH expression
is altered in ways other than somatic mutation, such as regulation
of mRNA levels. To date there are no studies to our knowledge
that suggest this is a possibility either in sporadic leiomyomas or
leiomyosarcomas. We are, however, in the process of evaluating
this possibility.
The mechanism by which FH can act as a tumour suppressor is
unclear. It is possible that hypermutability results from oxidative
damage. Alternatively, accumulation of fumarate leads to feedback
effects on oxidative metabolism and thus on the cell cycle. Smooth
muscle cells harbouring ‘two hits’ in FH would exhibit inhibition of
normal progression of the cell cycle, causing hyperproliferation or a
failure of apoptosis. Feedback from fumarate would have tissue-speci-
ﬁc effects, hence the growth of smooth muscle tumours (Tomlinson et
al, 2002). Although mutations in FH do not appear to be involved in
the development of sporadic smooth muscle tumours it is conceivable
that other mitochondrial defects may be involved.
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Table 1 Primers for PCR ampliﬁcation of the exons of FH
Exon Forward primer Reverse primer Size (bp)
1 TGTGAGGCTGTTGATTGGAT GGAGGGCTGAAGGTCACTG 298
2 GATGCGATTACTTTTGAT CATGAATACAGCCTACTT 256
3 AACTTCCATGCTTAAGTA ATCGTCATCCAGACTATG 230
4 GTCAACTGTATTCAAACT TTCAATTTATAACCAAAA 299
5 TTTTATATTTCTTTTGAA TTAAGCTAGTCAGATTTC 297
6 TAACTTGTAAGCTATTAG ACATGTTTGATGGAAAAA 355
7 TGTTTCACTTGCTAATGG GGTCCATAGCTAAGAATG 348
8 GCTTTATTGTATATCTTA TAGAAGTCTTTATGAAAT 311
9 CATGTTGCCTTAGTAATGTCTCTCTC TGCTGTTCTCAAACACTGATCC 261
10 ATGTCACCTTTTGCTTTA TCCGTTTTTAAGAAATGG 287
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